PeptideGlobal

Dunnhumby survey finds cost holds back GLP 1 use across the Americas as Brazil nears US levels

A dunnhumby survey of 8,500 consumers in six countries finds GLP-1 use highest in the United States and Brazil, nearly half of ever users stopped, and cost is the top barrier for people considering treatment.

Illustration for the story: Dunnhumby survey finds cost holds back GLP 1 use across the Americas as Brazil nears US levels

Illustration by Peptide Global, not a picture of the place in the story.

The short of itA dunnhumby survey of 8,500 adults in six countries of the Americas finds GLP-1 use highest in the United States and Brazil and cost the main barrier for people who want to start.

A new dunnhumby survey of 8,500 consumers across the Americas finds that cost, not lack of interest, is the main thing keeping would-be users off GLP-1 medicines. The customer data firm released the special edition of its Consumer Trends Tracker on 18 November. It shows Brazil close to the United States on use, high rates of stopping in Chile and Mexico, and low awareness in Colombia and Chile. The fieldwork took place in August 2026.

Use and awareness by country

The survey covered the United States, Brazil, Canada, Mexico, Colombia and Chile. The share of adults who have ever used a GLP-1 medicine was highest in the United States at 16.7 percent, followed closely by Brazil at 14.4 percent, according to the report as summarised by Supermarket News. Canada came next at 9.1 percent, then Mexico at 6.4 percent, with Colombia and Chile both at 4.5 percent. Outside Brazil, the firm said, adoption in Latin America is held back by awareness: only 43.8 percent of Colombians and 54.9 percent of Chileans had heard of these drugs at all. The report does not split use by brand or by medical reason, so diabetes and weight loss users are counted together.

Brazil stands out for another reason. It had the highest share of consumers changing what they eat and drink because they or someone at home takes a GLP-1, at 33 percent, ahead of the United States at 31.7 percent. Chile had the lowest, at 10 percent. Across the region, more than one in five adults now eat differently because of a user in their home, and each user shapes the food choices of more than two people on average. Brazil is also the market where cheaper semaglutide copies have arrived this year, including a generic from Dr Reddy's that won ANVISA approval for generic semaglutide this month, though the survey predates those launches.

Cost is the first barrier

Among adults who are considering a GLP-1 medicine, cost was the most common reason for not having started, cited by 26.6 percent. Access to a prescription came next at 19.6 percent, then side effects at 18.3 percent. Among people who have ruled the drugs out, only 5.1 percent pointed to cost, which suggests price mostly blocks those who already want treatment. In North America, cost was the main barrier for 37 percent of considering adults earning under $50,000 a year, against 23 percent of those earning more. The report did not give income splits for the Latin American countries, so it is not possible to say how strongly price weighs there compared with the north.

Among people who have ruled the drugs out, only 5.1 percent pointed to cost, which suggests price mostly blocks those who already want treatment.

Family status also mattered. In households with children, 24.8 percent of adults had considered a GLP-1, compared with 14.6 percent in homes without children, and actual use followed the same pattern at 12.3 percent against 8.2 percent across the Americas. Adults aged 25 to 44 were the most likely to consider the drugs. For health systems and insurers, these figures sketch the group most likely to start next: working age parents who are interested but held back by price or by the need for a prescription. The survey does not measure clinical need, so it cannot say how many of these people meet the medical criteria for treatment.

Many users stop

The dunnhumby survey also asked people who had ever used a GLP-1 whether they still do. Nearly half, 45.6 percent, had stopped, which means counts of current users understate how many people have tried the drugs. Stopping was most common in Chile, at 66.7 percent, and Mexico, at 51 percent, and least common in Canada, at 39 percent, and the United States, at 40.2 percent. The report as published does not say why people stopped, whether because of cost, side effects, supply or reaching a goal, and it does not separate people with diabetes from those using the drugs for weight. That gap limits what the stopping figures can tell doctors or payers.

CountryEver used a GLP-1Ever users who stoppedChanged diet due to a household user
United States16.7%40.2%31.7%
Brazil14.4%Not reported33%
Canada9.1%39%Not reported
Mexico6.4%51%Not reported
Colombia4.5%Not reportedNot reported
Chile4.5%66.7%10%

Cost may help explain the high stopping rates in Chile and Mexico, but the dunnhumby data give no reasons, so that link remains unproven. For comparison, a Korea obesity drug survey earlier this month found 10.3 percent of Korean adults had used or been prescribed such a drug in the past year, with young adults leading. Methods differ: the Korean poll asked about a single year, while this one asks about ever use. Readers should treat the country figures as consumer survey estimates rather than prescription counts, since they come from what respondents reported and not from pharmacy or insurance records.

What the food industry reads into it

The firm behind the report sells customer data to retailers, and its headline reading is about shopping baskets. Users said they cut spending most on bakery goods, alcoholic drinks and ready meals, and spent more on fresh produce, health care items and fresh meat. Jamie Samaha, dunnhumby's chief executive, said: "GLP-1s are not taking demand out of the grocery cart, it's creating an opportunity." Only 8 percent of users who cut back said nothing would win them back, and about half wanted lower sugar or higher protein options. Those findings matter to food companies more than to patients, and they come from a firm whose clients are retailers and consumer brands.

For a medicines desk, the more useful signal is what the dunnhumby survey says about access. Brazil already comes close to United States levels of use, and price is the leading barrier for those waiting to start. As generic semaglutide spreads in Brazil, Canada and other markets where Novo Nordisk patents have expired, the next wave of surveys will show whether lower prices bring in the considering group. Wire coverage of the report also stressed how far each user shapes what the rest of the household buys and eats. Until fresh data arrive, the August fieldwork gives a baseline taken before most of those generic launches reached pharmacy shelves.

Conclusion

The dunnhumby survey puts GLP-1 use in the Americas at its highest in the United States and Brazil, finds nearly half of ever users have stopped, and shows cost as the main hurdle for people who want to start. Its stopping and awareness gaps between countries are large, but the report gives no reasons for stopping and no clinical detail. The next tests are whether cheaper generics in Brazil and Canada lift use among considering adults, and whether later surveys explain why so many quit.

Why it matters in these markets

It is one of the few surveys that compares GLP-1 use, stopping and awareness across Latin America with the United States and Canada, just as cheaper generic semaglutide reaches Brazil and Canada.

What to watch

Whether generic semaglutide in Brazil and Canada lifts use among adults held back by cost, and whether later surveys explain why so many users stop, especially in Chile and Mexico.

Sources

  1. Supermarket News: GLP-1 influence on adults is growing in the Americas
  2. Yahoo Finance: GLP-1s shape diets of one in five adults in Americas, study shows

Spotted a wrong figure? Tell the desk; we fix errors under our corrections policy.

Peptide Global reports news about medicines and markets. Nothing here is medical or investment advice.